US agency questions AstraZeneca's Covid vaccine trial data
by Sarah Boseley Health editor from Science | The Guardian on (#5FP5D)
Drug firm may have provided incomplete view of efficacy data from US trial, says safety monitor
The Oxford/AstraZeneca vaccine against Covid has been dealt another blow within hours of AstraZeneca posting excellent results from its long-awaited big trial in the US.
Questions have been raised in the US by the independent Data and Safety Monitoring Board (DSMB), which has suggested that AstraZeneca may have provided outdated information" in its statement on Monday, which gave an incomplete view" of the results.
Continue reading...